表紙
市場調查報告書
商品編碼
225236

放射性醫藥品的全球市場

Radiopharmaceuticals

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 590 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球放射性醫藥品市場相關調查,彙整市場概要和競爭趨勢,產品概要,各地區的趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 序論
    • 現在及未來分析
    • 診斷用放射性醫藥品:壟斷的市場區隔
    • 心臟·腫瘤的放射性醫藥品
    • 新的治療用放射性醫藥品推動全球市場
    • 推動市場的要素
      • 癌症治療的接受性擴大
      • 疾病標靶治療的接受性擴大
      • 重視正確的診斷
      • 分子影像的應用
    • 阻礙市場的要素
      • 嚴格的法律規章指南
      • 全球供不應求
      • 價格敏銳度與競爭
    • 發展中國家趨勢 其他
  • 長期的推動成長要素
    • 癌症發病率上升
    • 各年齡容易罹癌的部位
    • 高齡化
    • 全球心血管疾病統計
  • 產品概要
    • 放射性醫藥品:定義
    • 作用機制
    • 放射性醫藥品的應用
    • 影像診斷的放射性描繪器
    • 治療方法
    • 研究
    • 殺菌
    • 放射性醫藥品的分類
    • 診斷用放射性醫藥品
    • 治療用放射性醫藥品
  • 產品技術創新/引進
  • 近幾年的產業活動
  • 主要企業
    • Actinium Pharmaceuticals, Inc.
    • Alliance Medical
    • Alseres Pharmaceuticals, Inc.
    • Avid Radiopharmaceuticals
    • Bayer HealthCare Pharmaceuticals
    • Bracco Diagnostics, Inc.
    • Cardinal Health, Inc.
    • GE Healthcare
    • Ion Beam Applications S.A
    • Immunomedics, Inc.
    • Jubilant Pharma
    • Lantheus Medical Imaging Inc.
    • Medi-Radiopharma Ltd
    • Nordion, Inc.
    • Peregrine Pharmaceuticals, Inc.
    • PETNET Solutions Inc.
    • Positron Corporation
    • Triad Isotopes, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美
目錄
Product Code: MCP-1889

Abstract:

Global Radiopharmaceuticals Market to Reach US$9.9 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at a CAGR of 9.4% over the analysis period 2020-2027.SPECT Radioisotopes, one of the segments analyzed in the report, is projected to grow at a 9.3% CAGR to reach US$4.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PET Radioisotopes segment is readjusted to a revised 9.5% CAGR for the next 7-year period. This segment currently accounts for a 24% share of the global Radiopharmaceuticals market.

The U.S. Accounts for Over 47.7% of Global Market Size in 2020, While China is Forecast to Grow at a 12.7% CAGR for the Period of 2020-2027

The Radiopharmaceuticals market in the U.S. is estimated at US$2.5 Billion in the year 2020. The country currently accounts for a 47.74% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$645.7 Million in the year 2027 trailing a CAGR of 12.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR while Rest of European market (as defined in the study) will reach US$645.7 Million by the year 2027.

Beta Emitters Segment Corners a 16.5% Share in 2020

In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$773.7 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$481.1 Million by the year 2027, while Latin America will expand at a 11.3% CAGR through the analysis period.

Select Competitors (Total 78 Featured) -

  • Actinium Pharmaceuticals, Inc.
  • Alliance Medical
  • Alseres Pharmaceuticals, Inc.
  • Avid Radiopharmaceuticals
  • Avid Bioservices Inc
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Ion Beam Applications S.A
  • Immunomedics, Inc.
  • Jubilant Pharma
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd
  • Nordion, Inc.
  • Novartis/Advanced Accelerator Applications
  • PETNET Solutions Inc.
  • Positron Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to Hinder Nuclear Medicine Procedures in Most Countries
    • Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in U.S Hospitals
    • Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals Struggling with Seamless Supply of Medical Radioisotopes
    • Nuclear Medicine Services Limp Back to Normality after Easing of COVID-19 Restrictions
    • COVID-19 Presents Generational Opportunity
    • Radiopharmaceuticals: A Prelude
    • Mechanism of Action
    • Global Supply Shortages Continue to Challenge Market Growth
    • EXHIBIT 1: A Glimpse at Mo-99 Processors Worldwide
    • EXHIBIT 2: Nuclear Research Reactor Irradiators Worldwide: A Snapshot
    • Outlook
    • Key Market Drivers
    • Market Restraints
    • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
    • Classification of Radiopharmaceuticals
    • Diagnostic Radiopharmaceuticals: The Dominant Segment
    • Key Drivers
    • Positron Emission Tomography (PET)
    • Major PET Isotopes and their Applications
    • Single Photon Emission Computed Tomography (SPECT)
    • Major Isotopes and their Diagnostic Applications
    • Therapeutic Radiopharmaceuticals
    • Select Isotopes and their Therapeutic Applications
    • Key Drivers
    • Competitive Landscape
    • EXHIBIT 3: Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2019
    • Recent Industry Activity
    • World Brands
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
    • Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
    • Advent of New Radiopharmaceuticals Widen Scope
    • Select New Products
    • Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
    • Select Commercially Available Therapeutic Radiopharmaceuticals
    • PET Eclipses SPECT in Cardiovascular Imaging
    • EXHIBIT 4: Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2019
    • Cardiac Amyloidosis Visualization: A Potential Application for PET
    • Innovative Radiopharmaceuticals to Boost Cardiac Applications
    • EXHIBIT 5: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Application of PET in Drug Development to Expand Opportunities
    • Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
    • Personalized Medicine Drives Nuclear Medicine
    • XHIBIT: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • EXHIBIT 6: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • Rise in Incidence of Neurological Disorders to Drive Growth
    • Rising Cancer Incidence Worldwide Spurs Demand
    • EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 8: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
    • EXHIBIT 9: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Ageing Population: A Vital Demography
    • EXHIBIT 10: Global Aging Population: Population of 65+ Individuals (in Thousands) by Region for 2019 and 2030
    • EXHIBIT 11: Global Cancer Deaths by Age Group (in %) for 2019
    • Rise in Healthcare Expenditure to Drive Growth
    • EXHIBIT 12: Elderly Healthcare Expenditure as a % of GDP
    • EXHIBIT 11: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Relevant Aspects of Radiopharmaceutical Production
    • Regulatory Regime Governing Production and Use of Radiopharmaceuticals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 3: World 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 6: World 11-Year Perspective for SPECT Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 9: World 11-Year Perspective for PET Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 12: World 11-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 15: World 11-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 18: World 11-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 21: World 11-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 24: World 11-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 27: World 11-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 30: World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 33: World 11-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 36: World 11-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 39: World 11-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Overview
    • Diagnostic Applications Stimulate Future Growth
    • Demographic Changes Offer Growth Opportunities
    • EXHIBIT 13: US Elderly Population: Expected Growth Rates Over the Years 2005-2025
    • Rising Incidence of Cancer: A Major Growth Driver
    • EXHIBIT 14: Leading Sites of New Cancer Cases in Males: 2020
    • EXHIBIT 15: Leading Sites of New Cancer Cases in Females: 2020
    • Cardiovascular Imaging to Lead Volume Growth
    • Radiopharmaceuticals Usage Strengthens in PET Imaging
    • Radioisotope/Radiopharmaceuticals Supply Scenario
    • Passing of Medicare Diagnostic Radiopharmaceutical Payment Equity Act
    • TABLE 40: USA Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 42: USA 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 45: USA 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 48: USA 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • CANADA
    • Market Overview
    • Efforts on to Address Mo-99 Supply Shortage
    • TABLE 49: Canada Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 51: Canada 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 52: Canada Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 54: Canada 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 55: Canada Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Canada Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 57: Canada 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • JAPAN
    • Market Overview
    • TABLE 58: Japan Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 60: Japan 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 61: Japan Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Japan Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 63: Japan 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 64: Japan Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Japan Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 66: Japan 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • CHINA
    • Market Overview
    • TABLE 67: China Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: China Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 69: China 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 70: China Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: China Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 72: China 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 73: China Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: China Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 75: China 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • EUROPE
    • Market Overview
    • TABLE 76: Europe Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 78: Europe 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2016, 2020 & 2027
    • TABLE 79: Europe Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 81: Europe 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 82: Europe Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 84: Europe 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 85: Europe Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 87: Europe 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • FRANCE
    • TABLE 88: France Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: France Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 90: France 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 91: France Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: France Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 93: France 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 94: France Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: France Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 96: France 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • GERMANY
    • TABLE 97: Germany Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Germany Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 99: Germany 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 100: Germany Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Germany Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 102: Germany 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 103: Germany Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Germany Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 105: Germany 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ITALY
    • TABLE 106: Italy Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Italy Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 108: Italy 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 109: Italy Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Italy Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 111: Italy 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 112: Italy Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Italy Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 114: Italy 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 115: UK Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UK Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 117: UK 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 118: UK Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: UK Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 120: UK 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 121: UK Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: UK Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 123: UK 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SPAIN
    • TABLE 124: Spain Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Spain Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 126: Spain 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 127: Spain Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Spain Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 129: Spain 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 130: Spain Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Spain Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 132: Spain 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • RUSSIA
    • TABLE 133: Russia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Russia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 135: Russia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 136: Russia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Russia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 138: Russia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 139: Russia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Russia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 141: Russia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF EUROPE
    • TABLE 142: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Rest of Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 144: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 145: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 147: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 148: Rest of Europe Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 150: Rest of Europe 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ASIA-PACIFIC
    • Market Overview
    • TABLE 151: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2016, 2020 & 2027
    • TABLE 154: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 156: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 157: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 159: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 160: Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 162: Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • AUSTRALIA
    • TABLE 163: Australia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Australia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 165: Australia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 166: Australia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Australia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 168: Australia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 169: Australia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Australia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 171: Australia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • INDIA
    • Market Overview
    • TABLE 172: India Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: India Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 174: India 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 175: India Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: India Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 177: India 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 178: India Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: India Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 180: India 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SOUTH KOREA
    • TABLE 181: South Korea Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: South Korea Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 183: South Korea 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 184: South Korea Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: South Korea Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 186: South Korea 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 187: South Korea Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: South Korea Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 189: South Korea 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 190: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 192: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 193: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 195: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 196: Rest of Asia-Pacific Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 198: Rest of Asia-Pacific 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • LATIN AMERICA
    • TABLE 199: Latin America Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 201: Latin America 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2016, 2020 & 2027
    • TABLE 202: Latin America Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 204: Latin America 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 205: Latin America Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 207: Latin America 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 208: Latin America Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 210: Latin America 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ARGENTINA
    • TABLE 211: Argentina Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Argentina Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 213: Argentina 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 214: Argentina Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Argentina Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 216: Argentina 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 217: Argentina Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Argentina Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 219: Argentina 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • BRAZIL
    • TABLE 220: Brazil Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Brazil Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 222: Brazil 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 223: Brazil Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Brazil Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 225: Brazil 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 226: Brazil Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Brazil Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 228: Brazil 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • MEXICO
    • TABLE 229: Mexico Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Mexico Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 231: Mexico 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 232: Mexico Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Mexico Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 234: Mexico 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 235: Mexico Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Mexico Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 237: Mexico 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 238: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Rest of Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 240: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 241: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Rest of Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 243: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 244: Rest of Latin America Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Rest of Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 246: Rest of Latin America 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • MIDDLE EAST
    • TABLE 247: Middle East Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 249: Middle East 11-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2016, 2020 & 2027
    • TABLE 250: Middle East Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 252: Middle East 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 253: Middle East Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 255: Middle East 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 256: Middle East Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 258: Middle East 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • IRAN
    • TABLE 259: Iran Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Iran Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 261: Iran 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 262: Iran Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Iran Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 264: Iran 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 265: Iran Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Iran Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 267: Iran 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • ISRAEL
    • TABLE 268: Israel Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Israel Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 270: Israel 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 271: Israel Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Israel Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 273: Israel 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 274: Israel Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Israel Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 276: Israel 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 277: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Saudi Arabia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 279: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 280: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Saudi Arabia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 282: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 283: Saudi Arabia Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Saudi Arabia Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 285: Saudi Arabia 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 286: UAE Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: UAE Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 288: UAE 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 289: UAE Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: UAE Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 291: UAE 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 292: UAE Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: UAE Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 294: UAE 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 295: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Rest of Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 297: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 298: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Rest of Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 300: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 301: Rest of Middle East Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Rest of Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 303: Rest of Middle East 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027
  • AFRICA
    • TABLE 304: Africa Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Africa Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 306: Africa 11-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2020 & 2027
    • TABLE 307: Africa Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Africa Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 309: Africa 11-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Neurology and Other Applications for the Years 2016, 2020 & 2027
    • TABLE 310: Africa Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Africa Historic Review for Radiopharmaceuticals by End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2019 and % CAGR
    • TABLE 312: Africa 11-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Ambulatory Surgical Centers and Other End-Uses for the Years 2016, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 77